AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 161 min read$LIFE

Wang Lingke sold $4.5M of LIFE

Wang Lingke (President) sold 118,333 shares of Ethos Technologies Inc. (LIFE) at an average of $38.36 ($37.64–$39.14, $4.54M total) across 3 trades on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wang Lingke
Published Oct 16, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LIFE
Bearish
high confidence
Mentioned
$LIFE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIFEBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a bearish signal, but the 10b5‑1 plan suggests it could be pre‑scheduled and not reflective of current sentiment.

02

Market read

Primary insider sale filing with modest dollar size; limited immediate market impact.

03

What to watch

No new operational or financial information accompanies the filing.

Relevance 5/10Novelty 5/10Timing: after-hours today

Background

SEC Form 4 filing by Ethos Technologies Inc. (LIFE) reporting an insider sale.

Company-level read

Ticker impact

$LIFEBearishHigh confidence
Context

Form 4 disclosed President Wang Lingke sold $4.5M of shares, reducing his stake to 1.54M shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A senior officer sold a sizable block via a 10b5-1 plan, which traders often view as a bearish signal.

Market effects

Sector

Minimal impact on the broader technology sector.

Regional

Limited to US markets where the stock trades.

Global

Low

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan, not indicative of company fundamentals.

Key entities

  • company
    Ethos Technologies Inc.

    Issuer of the stock LIFE.

  • person
    Wang Lingke

    President of Ethos Technologies, insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LIFE insider trading history →

Related articles

OCT 1
$LIFEMed

JPMorgan downgrades Ethos Technologies stock rating to neutral

JPMorgan downgraded Ethos Technologies (LIFE) to Neutral from Overweight, setting a $37 price target. The stock has surged 99% year-to-date. JPMorgan notes growth potential but cites balanced risk-reward and relative valuation concerns. Ethos reported Q2 2026 revenue of $189.6M, up 113% YoY, and raised full-year guidance to $727M-$731M. Other firms adjusted targets post-results.

investing.com2 min
SEP 3
$LIFEMed

Ethos (LIFE) Grows Revenue 113% While Margins Quietly Compress

Ethos Technologies (LIFE) reported Q2 revenue growth of 113% to $189.6M, with new policies up 133%. Gross profit margin was 98%, but net income rose only 5% to $19.5M. The company authorized a $100M stock buyback. Q3 revenue guidance is $160M-$164M, and full-year guidance is $727M-$731M. Margins compressed, with GAAP net loss of $146.9M for H1 2026 due to stock-based compensation.

insidermonkey.com3 min
AUG 11
$LIFEMedAI 9/10

Ethos (LIFE) Q2 2026 Earnings Call Transcript

Ethos Technologies (LIFE) reported Q2 2026 revenue of $189.6 million, up 113% Y/Y, with direct revenue $116.5 million (+131%) and third-party revenue $73.1 million (+90%). Adjusted EBITDA was $35.2 million (19% margin). Net income was $19.5 million. Full-year 2026 guidance: revenue $727-$731 million and adjusted EBITDA $119-$123 million. Up to $100 million Class A repurchase authorized.

fool.com7 min
AUG 5
$LIFEMed

Top SMid Cap Pick: Ethos Technologies Leads Citi’s Rankings

Citi analyst Ronald Josey named Ethos Technologies (LIFE) his top SMID-cap pick after the company’s Q2 results. Activated policies growth accelerated to 133% YoY, with 107,800 net activated policies. Revenue rose to $189.6M (+113% YoY). Ethos raised 2026 revenue guidance to $727M-$731M and adjusted EBITDA to $119M-$123M. Citi lifted its price target to $33 and kept Buy/High Risk.

investing.com4 min